Compass Therapeutics (CMPX) Change in Account Payables (2019 - 2026)
Compass Therapeutics recorded quarterly Change in Account Payables of -$679000.0 in Q1 2026, up 55.03% quarter-over-quarter from -$1.5 million in Q4 2025, and down 1.04% year-over-year from -$686147.4 in Q1 2025.
Compass Therapeutics' Change in Account Payables history runs 8 years deep, the most recent figure standing at -$679000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables fell 1.04% year-over-year to -$679000.0; the TTM figure through Mar 2026 stood at -$671000.0 (down 192.81% YoY), while the FY2025 annual figure was -$664000.0, up 63.93% from the prior year.
- Change in Account Payables came in at -$679000.0 for Q1 2026 at Compass Therapeutics, up from -$1.5 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $6.2 million in Q2 2022 to a low of -$3.7 million in Q3 2022.
- A 5-year average of $2294.1 and a median of -$232000.0 in 2024 frame the typical range for Change in Account Payables.
- On a YoY basis, Change in Account Payables climbed as much as 62200.0% in 2022 and fell as far as 1295.47% in 2022.
- Compass Therapeutics' Change in Account Payables stood at $621000.0 in 2022, then surged by 187.28% to $1.8 million in 2023, then dropped by 27.75% to $1.3 million in 2024, then tumbled by 217.15% to -$1.5 million in 2025, then soared by 55.03% to -$679000.0 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$679000.0, -$1.5 million, and $500000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | -679,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -679,000.00 |
| Mar 31, 2026 | -679,000.00 |
| Dec 31, 2025 | -1.51 Mn |
| Dec 31, 2025 | -1.51 Mn |
| Sep 30, 2025 | 500,000.00 |
| Sep 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 1.02 Mn |
| Mar 31, 2025 | -672,000.00 |
| Mar 31, 2025 | -672,000.00 |
| Dec 31, 2024 | 1.29 Mn |
| Dec 31, 2024 | 1.29 Mn |
| Sep 30, 2024 | -232,000.00 |
| Sep 30, 2024 | -232,000.00 |
| Jun 30, 2024 | 338,000.00 |
| Jun 30, 2024 | 338,000.00 |
| Mar 31, 2024 | -3.24 Mn |
| Mar 31, 2024 | -3.24 Mn |
| Dec 31, 2023 | 1.78 Mn |
| Dec 31, 2023 | 1.78 Mn |
| Sep 30, 2023 | 1.58 Mn |
| Sep 30, 2023 | 1.58 Mn |
| Jun 30, 2023 | -401,000.00 |
| Jun 30, 2023 | -401,000.00 |
| Mar 31, 2023 | -2.26 Mn |
| Mar 31, 2023 | -2.26 Mn |
| Dec 31, 2022 | 621,000.00 |
| Dec 31, 2022 | 621,000.00 |
| Sep 30, 2022 | -3.69 Mn |
| Sep 30, 2022 | -3.69 Mn |
| Jun 30, 2022 | 6.20 Mn |
| Jun 30, 2022 | 6.20 Mn |
| Mar 31, 2022 | -611,000.00 |
| Mar 31, 2022 | -611,000.00 |
| Dec 31, 2021 | -1,000.00 |
| Dec 31, 2021 | -1,000.00 |
| Sep 30, 2021 | 309,000.00 |
| Sep 30, 2021 | 309,000.00 |
| Jun 20, 2021 | -502,000.00 |
| Jun 20, 2021 | -502,000.00 |
| Sep 30, 2020 | 194,000.00 |
| Sep 30, 2020 | 194,000.00 |
| Jun 30, 2020 | 952,000.00 |
| Jun 30, 2020 | 952,000.00 |
| Mar 31, 2020 | -285,000.00 |
| Mar 31, 2020 | -285,000.00 |
| Sep 30, 2019 | -1.10 Mn |
| Sep 30, 2019 | -1.10 Mn |
| Jun 30, 2019 | -1.28 Mn |
| Jun 30, 2019 | -1.28 Mn |